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HypoxiaSirtuins or Sir2 family of proteins are a class of NAD+ dependent protein deacetylases which are evolutionarily
conserved from bacteria to humans. Some sirtuins also exhibit mono-ADP ribosyl transferase, demalonylation
and desuccinylation activities. Originally identiﬁed in the yeast, these proteins regulate key cellular processes
like cell cycle, apoptosis, metabolic regulation and inﬂammation. Humans encode seven sirtuin isoforms
SIRT1–SIRT7 with varying intracellular distribution. Apart from their classic role as histone deacetylases regulat-
ing transcription, a number of cytoplasmic and mitochondrial targets of sirtuins have also been identiﬁed.
Sirtuins have been implicated in longevity and accumulating evidence indicate their role in a spectrum of dis-
eases like cancer, diabetes, obesity and neurodegenerative diseases. A number of studies have reported profound
changes in SIRT1 expression and activity linked tomitochondrial functional alterations following hypoxic–ische-
mic conditions and following reoxygenation injury. The SIRT1mediated deacetylation of targets such as PGC-1α,
FOXO3, p53 andNF-κb has profound effect onmitochondrial function, apoptosis and inﬂammation. These biolog-
ical processes and functions are critical in life-span determination and outcome following injury. Aging is report-
ed to be characterized by declining SIRT1 activity, and its increased expression or activation demonstrated
prolonged life-span in lower forms of animals. A pseudohypoxic state due to declining NAD+ has also been
implicated in aging. In this review we provide an overview of studies on the role of sirtuins in aging and injury.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Protein acetylation is a post translational modiﬁcation that regulates
key cellular functions including DNA recognition, protein–protein
interaction, catalytic activity and protein stability [1–3]. The protein
acetylation and deacetylation at N-epsilon lysine residues are catalyzed
by histone acetyltransferases (HATs) and histone deacetylases (HDACs)
respectively [4]. There are four classes of HDACs, Classes I–IV, based on
phylogenetic analysis of all HDAC-related proteins [5]. Sirtuins are
classiﬁed as Class III HDACs that are homologous to yeast transcriptional
repressor, Sir2 [4]. Themajor functional difference between sirtuins and
other HDACs is that sirtuins catalyze deacetylation of substrate proteins
in a reaction that consumes NAD+. These protein modifying enzymes
play signiﬁcant roles in diverse cellular processes like apoptosis [6,7],
mitochondrial biogenesis [8], lipid metabolism [9], fatty acid oxidation
[9,10], cellular stress response [11–14], insulin secretion [15], aging
[16–19] and inﬂammation [20].
2. Biochemistry of sirtuins
Studies on mating type regulation in yeast Saccharomyces cerevisiae
identiﬁed the ﬁrst sirtuin, Sir2 (silent information regulator 2) [21,22].CB2601, Sanders Building, 1479The initial evidences of the enzymatic activity of sirtuins came from
studies on Sir2. Using 32P-labeled NAD it was shown that human
ortholog of yeast Sir2 can transfer 32P fromNAD+ to bovine serum albu-
min, suggesting the role of Sir2 in mono ADP ribosylation of proteins
[23]. The observed enzymatic activity of Sir2 was found to be critical
for the transcriptional repression at the silent mating-type loci,
telomeric DNA regions, and the rDNA repeats [24]. The role of sirtuins
as histone deacetylases was better characterized following molecular
analysis of lysine residues of speciﬁc histone subunits [25–27]. Imai
et al. analyzed the product formed from Sir2 reaction by HPLC and
mass spectrometry, and together with supporting data from
mutational studies on conserved residues of the core domain of Sir2
concluded that NAD+ dependent deacetylase activity, rather than
ADP-ribosyltransferase activity, account for Sir2 functions in vivo [25].
The histone deacetylation by Sir2 is coupled to NAD breakdown
resulting in the formation of deacetylated protein, nicotinamide
(NAM) and O-acetyl-ADP-ribose (OAADPr) [28]. The deacetylation
reaction catalyzed by Sir2 is represented in Fig. 1. The absolute require-
ment of NAD+ in the reaction, unlike the reactions catalyzed by other
known protein deacetylases, makes their chemistry complex and
energetically more demanding. However, the beneﬁt of this seem-
ingly expensive reaction is its intricate regulation in multiple ways
including by its own reaction products. The catalytic activity of Sir2
function is regulated by dynamic changes in cellular NAD+ concentra-
tion or the NAD+/NADH ratio [29,30]. Cellular levels of nicotinamide
phosphoribosyltransferase (Nampt), the rate-limiting enzyme for
Fig. 1. Protein deacetylation by Sir2. Sir2 catalyzes the transfer of acetyl group from the protein to ADP-ribose moiety of NAD+ to form O-acetyl-ADP-ribose (OAADPr) and nicotinamide
(NAM). Nicotinamide phosphoribosyltransferase (Nampt), the rate limiting enzyme in NAD biosynthetic pathway converts NAM to nicotinamide mononucleotide (NMN). NMN is then
converted to NAD by nicotinamide mononucleotide adenylyltransferase (Nmnat). Another NAD salvage pathway component, Pnc1, converts NAM to nicotinic acid.
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and hence affect sirtuin activity [31]. NAM is a potent inhibitor of
sirtuin-mediated deacetylation [32]. PNC1 (pyrazinamidase/
nicotinamidase 1), which encodes an enzyme that deamidates nicotin-
amide, converts NAM to nicotinic acid by a salvage pathway and
regulates NAM accumulation [33]. Therefore both PNC1 and NAM can
modulate Sir2 activity in the cells. In addition, OAADPr, another product
of Sir2 mediated deacetylation, is also increasingly recognized as an im-
portant metabolic by-product [34,35]. OAADPr was found to regulate
gene silencing by facilitating the assembly and loading of the Sir2-4 si-
lencing complex onto nucleosomes [36,37]. Moreover, it is also a sub-
strate for deacetylation by cellular macrodomain proteins like human
MacroD1, human MacroD2, Escherichia coli YmdB, and the sirtuin-
linked MacroD-like protein from Staphylococcus aureus [38]. Therefore,
the deacetylation catalyzed by Sir2 serves critical functions in cellular
homeostasis.
Sir2 gene family is highly conserved from bacteria to humans sug-
gesting a commonmechanismof gene silencing across the phylogenetic
domains [39]. The bacterial and archaeal sirtuins play important roles in
regulating transcription and cellular processes. For instance, bacterial
sirtuin CobB is an enzyme involved in propionate catabolism and cobal-
amin biosynthesis [40]. It deacetylates and activates acetyl-CoA synthe-
tase in anNAD-dependentmanner [41] and regulates E. coli chemotaxis
by deacetylating CheY [42]. These ﬁndings suggest that both eukaryotes
and prokaryotes carry out lysine acetylation as a common regulatory
mechanism [41]. Studies also suggest a role for protein acetylation and
deacetylation in bacterial stress response systems [43]. The archael
sir2 homolog from Sulfolobus solfataricus P2 has both NAD-dependent
deacetylase and mono-ADP-ribosyl transferase activities and regulate
the binding of DNA binding protein alba [44].
Crystal structures of bacterial, yeast and mammalian sirtuins have
been elucidated and reveal a highly conserved core domain made of a
larger region with Rossmann-fold structure and a smaller variable re-
gion with zinc ribbon motif [45–47]. The sirtuins also contain N-and
C-terminal extensions outside the catalytic core which are not con-
served [47]. Prokaryotes generally contain one or two sirtuin genes
whereas eukaryotes encode multiple isoforms. Yeasts contain the
foundingmember Sir2 and four homologs of Sir2 (HST1-4).Mammalian
sirtuin system is composed of seven genes; SIRT1 to SIRT7 amongwhich
SIRT1 has the highest sequence similarity to yeast Sir2 [48]. Sirtuins
from a diverse number of organisms were phylogenetically analyzed
and organized in to 5 major classes (I, II, III, IV and U) [48]. Class 1 com-
prises 5 yeast sirtuins (Sir2 andHST proteins) and human sirtuins SIRT1,
SIRT2 and SIRT3. Class II has mammalian SIRT4 and sirtuins from other
eukaryotes and bacteria. Class III hasmammalian SIRT5 aswell as bacte-
rial and archael sirtuins. Most bacterial sirtuins belong to Class III. Class
IV includesmammalian SIRT6 and 7. Class U contains sirtuins fromgram
positive bacteria and Thermotoga maritima.2.1. An overview of mammalian sirtuins
Mammalian sirtuins differ in their subcellular localization and func-
tion. SIRT1, SIRT6 and SIRT7 are mainly nuclear proteins with distinct
subnuclear compartmentalization [49]. SIRT3, SIRT4 and SIRT5 are local-
ized tomitochondria whereas SIRT2 is predominantly cytoplasmic [49].
While SIRT1-3 have strong deacetylase activity, SIRT4-7 are reported to
have weak or no detectable deacetylase activity [50–52]; SIRT4 has
predominantly ADP ribosyl transferase activity [53]. Table 1 represents
the different mammalian sirtuins, their localization, and intracellular
targets.2.1.1. SIRT1
SIRT1, the mammalian ortholog of yeast Sir2, is the most studied
mammalian sirtuin. SIRT1 plays important roles in embryonic develop-
ment [149,150] and skeletal muscle differentiation [151]. It has diverse
functions in the cells ranging from chromatin modiﬁcation and epige-
netics to roles inmetabolic pathways, inﬂammation and stress response
(Fig. 2) [152]. It interacts with and deacetylates histones and a number
of non-histone substrates. SIRT1 preferentially deacetylates speciﬁc
residues in histone subunits like the lysine 16 of histone 4 (H4K16),
lysine 9 of histone 3 (H3K9), lysine 56 of histone 3 (H3K56) [153] and
lysine 26 of histone 1 to promote heterochromatin formation and tran-
scriptional silencing [54,55]. The non-histone protein substrates of
SIRT1 include but not limited to tumor suppressor p53, nuclear factor-
κB (NF-κB), peroxisome proliferator-activated receptor gamma coacti-
vator 1-alpha (PGC-1α), fork-head box protein O (FOXO) transcription
factors, liver X receptor (LXR), PARP, Ku70 and hypoxia-inducible factor
(HIF)-1α [154,11,58,60,61,65,70,85,155]. SIRT1 plays a predominant
role in regulating apoptosis through deacetylating p53 and inhibiting
p53 dependent transcription during cellular stress [56,150,156]. It also
controls inﬂammation through regulating NF-κB signaling by
deacetylating the p65 subunit of the complex thereby inhibiting NF-κB
signaling. On the contrary, NF-κB signaling diminishes SIRT1 activity
by modulating expression of miR-34a, IFNγ, and reactive oxygen
species [57]. miR-34a, a tumor suppressor, has been reported to bind di-
rectly to 3′-UTR of SIRT1 thereby repressing its expression and enhanc-
ing p53mediated apoptosis [157] . It has been also known that miR-34a
is a transcriptional target of p53 [157,158]. Furthermore, Kim et al. dem-
onstrated that p53 is inﬂuenced in miR-34a-mediated repression of
SIRT1 in cisplatin-induced cytotoxicity [159]. The antagonistic crosstalk
between SIRT1 and NF-κB signaling is apparent in many inﬂammatory
diseases and aging [160–163]. Moreover, inﬂammation associated
increase in nitric oxide (NO) production results in S-nitrosylation and
inhibition of SIRT1 activity which further heightens the inﬂammatory
response through increased acetylation of p65 [164]. In addition,
SIRT1 has demonstrated role as a tumor suppressor in rodent studies
Table 1.
Sirtuins: Intracellular Localization, Substrates and Function.
Sirtuin Localization Substrates Enzymatic activity
SIRT1 Nuclear,
cytoplasmic
Histone H1 [54], Histone H3 [54], Histone H4 [55], p53 [56], NF-κB [57], FOXO4 [58], PGC1α [59], HIF1α [60],
HIF2α [61], CTIP2 [62], Tat [63], p300 [64], LXR [65], FXR [66], eNOS [67], MEF2 [68], Notch1 [69], Ku70 [70],
XPA [71], WRN [72], NBS1 [73], LKB1 [74], AceCS1 [75], HMGCS1 [76], c-Myc [77], androgen receptor [78],
SUV39H1 [79], BMAL1 [80], PER2 [81], DNMT1 [82], hMOF [83], TIP60 [83], cortactin [84], PARP1 [85],
SREBP-1C [64], SATB1 [86], RFX-5 [87], TDG [88], FOXA2 [89], IRF-1 [90], HMGB1 [91],




Histone H4 [96], Histone H3 [97], Tubulin [98], FOXO1 [99], FOXO3A [100], p53 [101], p300 [102], p65 [103],
PEPCK1 [104], Par-3 [105], CDK9 [106], HIF1α [107], G6PD [108], PGAM [109], ALDH1A1 [110], TUG [111],
BubR1 [112], beta-secretase 1 [113].
Deacetylation, demyristoylase
SIRT3 Mitochondrial AceCS2 [75], HMGCS2 [114], LCAD [115], SDH [116], Ku70 [117], SOD2 [118], IDH2 [119], GDH [120], LKB1
[121], MRPL10 [122], LCAD [10]; ATP synthase F1 [123], Cyclophilin D [124], OTC [125], ALDH2 [126], Skp2
[127], FOXO3 [128], PDH [129], OGG1 [130], OPA1 [131], Hsp10 [132], GOT2 [133], MDH [113],
Aconitase 2 [113].
Deacetylation
SIRT4 Mitochondrial GDH [53], MCD [134], PDH [135], Hsp60 [113], Stress-70 [113], Nnt [113]. ADP-ribosylation, deacetylation,
lipoamidase
SIRT5 Mitochondrial Cytochrome C [120], CPS1 [136], SOD1 [137], Urate oxidase [138], PML [95], VLCAD [139], Prx-1 [113],
HMGCS2 [113], Hsp70 [113], MCAD [113].
Deacetylation, Demalonylation,
Desuccinylation, Deglutarylation
SIRT6 Nuclear TNFα [140], Histone H3 [51], CtIP [141], PARP1 [142], GCN5 [143], KAP1 [144], GEN1 [113], Kup86 [113],
p70 [113].
Deacetylation, ADP-ribosylation
SIRT7 Nucleolus Histone H3 [145], PAF53 [146], GABPβ1 [147], p53 [148], MEF-2C [113], DNA-PK [113] Deacetylation
Abbreviations: AceCS, acetyl-CoA Synthase; ALDH, aldehyde dehydrogenase; CDK9, cyclin-dependent kinase 9; CPS1, carbamoyl phosphate synthetase 1; CtIP, C-terminal binding protein;
CTIP2, chicken ovalbuminupstreampromoter transcription factor interacting protein 2; CRABPII, cellular retinoic acid binding protein II; DNA-PK, DNA-dependent protein kinase; DNMT1,
DNA methyltransferase 1; eNOS, endothelial nitric oxide synthase; FOX, forkhead transcription factor; FXR, farnesoid X receptor; GABPβ1, GA binding protein 1; GCN5, General Control
Non-repressed Protein 5; GDH, glutamate dehydrogenase; G6PD, glucose-6-phosphate dehydrogenase; GOT2, glutamate oxaloacetate transaminase 2; HMGB1, high-mobility group
box 1; HMGCS, 3-hydroxy-3-methylglutaryl CoA synthase; hMOF, human ortholog of the Drosophila males-absent-on-the-ﬁrst; Hsp10, heat shock protein 10; IDH2, isocitrate dehydro-
genase 2; IRF-1, interferon regulatory factor 1; KAP1, KRAB-associated protein 1; LCAD, long-chain acyl coenzyme A dehydrogenase; LKB1, liver kinase B1; LXR, liver X receptor; MCAD,
medium-chain acyl-CoA dehydrogenase;MCD,malonyl CoA decarboxylase;MDH,malate dehydrogenase;MEF2,myocyte enhancer factor 2; NBS, nijmegen breakage syndrome;Nnt, nic-
otinamide nucleotide transhydrogenase;OGG1, 8-oxoguanine-DNAglycosylase 1;OPA1, optic atrophy 1; PAF53, polymerase-associated factor 53; PARP1, poly(ADP-ribose) polymerase 1;
PDH, pyruvate dehydrogenase; PEPCK1, phosphoenolpyruvate carboxykinase; PER2, period 2; PGAM, phosphoglyceratemutase; PML, Prx-1, peroxiredoxin 1; RFX-5, regulatory factor for
X-box; SATB1, special AT-rich sequence-binding protein-1; Skp2, S-phase kinase associated protein 2; SOD2, superoxide dismutase 2; SUV39H1, suppressor of variegation 3-9 homolog 1;
TDG, thymine DNA glycosylase; TIP60, HIV-1 TAT-interacting protein of 60 kDa; TopBP1, DNA topoisomerase 2-binding protein 1; XPA, xeroderma pigmentosum group A
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transcriptional activity [165,166].
SIRT1 plays a major role in metabolic regulation and PGC-1a
deacetylation is one of the important events in this process. Hepatic
SIRT1 has been suggested to play an important role in glucose and
lipid metabolism in fasting [167]. SIRT1 has a vital role in maintaining
lipid homeostasis through PPARα mediated beta-oxidation of fatty
acids in the liver [9] and mobilization of fat fromwhite adipocytes dur-
ing fasting [168]. In addition, SIRT1 controls mitochondrial biogenesis
though regulating PGC-1α pathway [59]. SIRT1 negatively regulates
the expression and phosphorylation of signal transducer and activator
of transcription 3 (STAT3) and STAT3 mediated cellular respirationFig. 2. SIRT1 regulation in health and disease. Increased SIRT1 activity results in deacet[169]. A noteworthy aspect of SIRT1 mediated metabolic control is its
regulation by AMPK which is also known as the cellular fuel gauge.
AMPK activation has been reported to enhance SIRT1 activity by in-
creasing NAD+ levels resulting in deacetylation of SIRT1 targets [170].
Conversely, SIRT1 activation is reported to induce AMPK activation by
deacetylation of AMPK upstream kinase, LKB1 [74]. Adipokines like
adiponectin have been shown to stimulate AMPK–SIRT1–PGC-1α path-
way and increase mitochondrial content in myocytes [74]. Another key
feature of SIRT1 is its positive regulation on insulin secretion in
pancreatic β cells by repressing uncoupling protein2 (UCP2) gene
[171]. The SIRT1 localization and/or enzymatic activity is subjected to
regulation by post-translational modiﬁcations like phosphorylationylation of histone and nonhistone substrates affecting multiple cellular processes.
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[174]. The pleiotropic roles of SIRT1 in the cells make it an important
intracellular marker protein in aging as well as different diseases like
cardiovascular diseases, diabetes, cancer, neurodegenerative diseases
and other conditions in health and disease (Fig. 3) [152].
2.1.2. SIRT2
SIRT2 is themammalian ortholog of yeast Hst2 and is predominantly
cytoplasmic. It deacetylates α-tubulin [98]. SIRT2 protein levels often
ﬂuctuate during cell cycle, with a marked increase in expression and
phosphorylation during the mitotic and G2/M transition phase playing
a role in mitotic exit during cell cycle [175]. A characteristic feature of
SIRT2 is itsmigration to the nucleus duringG2/M transition tomodulate
chromatin condensation by histone H4 deacetylation [96]. SIRT2 can
also deacetylate FOXO1 and promote FOXO1 binding to PPARγ resulting
in the suppression of PPARγ activity andhence adipocyte differentiation
[99]. It also deacetylates FOXO3A to promote expression of antioxidant
and pro-apoptotic molecules under cellular stress [100]. A recent study
suggests that cells sense extracellular oxidative stimuli to decrease
acetylation of a key enzyme in the pentose phosphate pathway,
glucose-6-phosphate dehydrogenase, in a SIRT2-dependent manner
[108]. SIRT2 has been implicated in a number of diseases such as cancer
and neurodegenerative disorders like Parkinson's and Huntington's
disease [176].
2.1.3. SIRT3
SIRT3 is an NAD+ dependent deacetylase predominantly located in
themitochondrial matrix. Inactive SIRT3 has been shown to be convert-
ed to an active form in thematrix following its cleavage bymitochondri-
al matrix processing peptidase [177]. It is highly expressed in tissues
rich in mitochondria [178] and has a role in brown adipose tissue ther-
mogenesis [179]. Another group reported the presence of enzymatically
active full length SIRT3 in the nucleus which gets transported to the
mitochondria under conditions of cellular stress [180]. However, a
later study by Cooper et al. demonstrated an exclusive mitochondrial
localization of human SIRT3 [180]. Consistent with its localization in
mitochondria, loss of SIRT3 in a mouse model markedly elevated mito-
chondrial lysine acetylation [178]. SIRT3 loss resulted in a reduction in
basal ATP levels in multiple organs, hyperacetylation of complex I
components, and reduction in complex I activity [181]. The ﬁrst SIRT3
substrate identiﬁed was mitochondrial enzyme acetyl-CoA synthetase
2, the deacetylation of which leads to its activation [182]. SIRT3 acts as
a stress responsive protein in the cardiomyocytes by deacetylating
Ku70 and promoting its interaction with proapoptotic protein Bax
thereby preventing Bax translocation to themitochondria [117]. Anoth-
er SIRT3 interacting partner ismitochondrial complex I protein NDUFA9Fig. 3. SIRT1modulation in aging and injury. SIRT1 expression and/ or activity are upregulatedw
tection following injury.[181]. Two critical targets of SIRT3 deacetylation are mitochondrial
superoxide dismutase (SOD2) and isocitrate dehydrogenase 2 (IDH2),
the enhanced activity of these redox enzymes prevents accumulation
of toxic ROS. By regulatingROSproduction, SIRT3 suppresses the hypox-
ia inducible factor 1α (HIF-1α) transcriptional activity and hence may
act as a tumor suppressor [183]. SIRT3 has been reported to promote
mitochondrial fatty acid oxidation by deacetylating long-chain acyl
coenzyme A dehydrogenase, key enzyme involved in the oxidation of
long-chain substrates [10]. A recent study suggests that a natural
polyphenolic, Honokiol, blocks and reverses cardiac hypertrophy in
mice by activating mitochondrial SIRT3 [184]. Taken together, it may
be concluded that SIRT3 plays a signiﬁcant role in maintaining
mitochondrial homeostasis.2.1.4. SIRT4
SIRT4 is an NAD+ dependent ADP-ribosyl transferase localized to
the mitochondria. Insulin secretion in pancreatic β cells is subjected to
modulation by SIRT4 as secretion of insulin granules is triggered by
local increase in ATP concentration by enzymes like glutamate dehydro-
genase (GDH) that undergoes inhibition by SIRT4ADP-ribosylation [53].
Another notable function of SIRT4 is its regulatory control over gluta-
mine metabolism to facilitate DNA damage responses and to prevent
tumorogenesis [185]. Consistently,mTORC1 pathwaywhich is activated
in proliferating tumor cells downregulates SIRT4 expression [186]. Its
deacetylase activity is reported to regulate hepatic lipid homeostasis
[134]. SIRT4 was recently shown to possess lipoamidase function that
inhibits the activity of pyruvate dehyrogenase, an enzyme that links
glycolysis to citric acid cycle [135]. Together, these studies highlight a
major role for SIRT4 in regulating cellular metabolism and preventing
tumorogenesis.2.1.5. SIRT5
Mitochondrial SIRT5 is an NAD+ dependent protein lysine
demalonylase, desuccinylase [52] and a deglutarylase [187]. It plays a
pivotal role in ammonia detoxiﬁcation by deacetylating carbamoyl
phosphate synthetase 1(CPS1), the rate limiting step in urea cycle
[136]. In fact SIRT5 knockout mice had higher ammonia levels in blood
during fasting or with a high protein diet [136]. CPS1 is also a target of
desuccinylation [52] and deglutarylation by SIRT5 [187]. Other key tar-
gets of SIRT5 include SOD1 [137] andmitochondrial urate oxidase [138].
A recent study has reported its role in desuccinylating a key fatty acid
oxidizing enzyme and promoting fatty acid oxidation [139]. Although
loss of SIRT5 leads to hypersuccinylation of several metabolic pathway
components [188], it is considered a dispensable isoform in terms of
regulating metabolism [189].ith caloric restriction, ischemic preconditioning and STACS resulting in longevity and pro-
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SIRT6 is localized to nucleus and its enzymatic activities include
deacetylation of histones, ADP ribosylase and lysine deacylase [190].
SIRT6 mediated lysine deacylation of tumor necrosis factor-α (TNF-α)
promotes its secretion from macrophages [140]. SIRT6 is reported to
have a crucial role in maintaining genomic stability and repairing DNA
damages by different mechanisms [190]. It has a profound effect on
glucose metabolism by suppressing the expression of HIF-1α and
other glycolytic genes [191]. Hence a loss of SIRT6 resulted in severe
hypoglycemia due to increased glucose uptake inmuscle and fat tissues.
It also exerts control over hepatic gluconeogenesis by regulating
PGC-1α acetylation in an indirect manner through modifying the activ-
ity of acetyltransferase GCN5 [143]. Additionally, SIRT6 is involved in
lipid metabolism by negatively regulating triglyceride synthesis [192].
Like SIRT1, SIRT6 expression is correlated with longevity; its expression
decreased with age in human dermal ﬁbroblasts [193] and overexpres-
sion in male mice increased its life span [18]. SIRT6 function has also
been implicated in several different types of cancers [190]. Collectively,
these studies reveal major roles for SIRT6 in metabolism and aging.
2.1.7. SIRT7
SIRT7 has been shown to be expressed in the nucleolus where it
interacts with histones and RNA polymerase I to positively regulate
ribosomal gene (rDNA) transcription [194]. It is phosphorylated during
mitosis when the rDNA transcription is repressed and undergoes
dephosphorylation and conformational changes to resume rDNA
transcription at the exit from mitosis [195]. It is also proposed to play
a key role in connecting the chromatin remodeling complexes to RNA
Pol I machinery during transcription [196]. Initially an anti-
proliferative role for SIRT7was described in a mousemodel andmurine
cell lines [197]. In stark contrast, it was shown to deacetylate and
repress transcription of genes linked to tumor suppression, thus main-
taining oncogenic transformation [145]. The oncogenic potential of
SIRT7 was further demonstrated in human hepatocarcinomas [198]
and human colorectal cancer [199]. Other notable functions of SIRT7
include its role in ribosomebiogenesis and protein synthesis [200], inhi-
bition of hypoxia-inducible factor HIF-1α and HIF-2α [201], cofactor for
transcriptional repression by Myc [202] and hepatic lipid metabolism
[203]. A recent study reported its positive inﬂuence on mitochondrial
homeostasis by regulating acetylation of GABPβ1, a master regulator
of nuclear-encoded mitochondrial genes [147]. SIRT7 is considered a
potential target for cancer therapy and studies continue to unravel
novel roles for SIRT7.
2.2. Role of sirtuins in aging
The role of sirtuins in extending organism life span has been a topic
of great interest among researchers of aging. The functional relevance of
sirtuins in mitochondrial bioenergetics and oxidative stress coupled
with the observation that some of the sirtuins prolonged life
prompted extensive studies on sirtuin family of proteins in aging
biology. Though most of the studies on sirtuins were focused
towards elucidating the functional role of SIRT1, other members of
this family are also being studied to understand their role in aging,
health and disease [204].
The initial results on the effect of Sir2 on life-span in yeast was
further extrapolated into other model organisms like Drosophila,
Caenorhabditis elegans and rodents [16,18,205,206]. In yeast, Sir2 muta-
tion shortened lifespan owing to accumulation of toxic extrachromo-
somal rDNA circles (ERC) whereas Sir2 overexpression extended life
span by silencing HM loci and inhibiting ERC formation [205]. Sir2 was
found to mediate the life span extension in yeast induced by caloric re-
striction [207] by increasing mitochondrial oxidation and respiration
[208]. Life span may be extended by limiting activity of glucose-
sensing cyclic-AMP-dependent kinase (PKA) which requires Sir2 and
NAD [208]. Studies have also uncovered the role of nicotinamideclearance by PNC1 in regulating longevity by CR in yeast [33,209].
Aging is reported to decrease tissue levels of NAD resulting in declined
SIRT1 activity and decreasedNAD+/NADH leading to increased ROS for-
mation in mitochondria [210]. Another theory is the suppression of tar-
get of rapamycin (TOR) signaling pathway by CR [211] which leads to
inhibition of ribosome biogenesis and relocalization of the transcription
factorsMsn2p andMsn4p from the cytoplasm to the nucleus thereby in-
creasing expression of PNC1 [212].
Consistent with a role for Sir2, its activator resveratrol was found to
mimic CR induced longevity in the yeast [2] and sirtuin activating
compounds (STACs) delayed aging in metazoans [213]. However the
involvement of Sir2 or other homologs [214] in CR induced longevity
has also been questioned in some studies [215–217]. For instance, CR
was reported to enhance longevity in yeast cells lacking Sir2, implying
a Sir2 independent mechanism [215]. Conforming to this observation,
Sir2 homolog Hst2 was shown to mediate SIR2-independent life-span
extension by CR [214]. Contrary to the above, another report precludes
the involvement of any Sir2 familymembers in lifespan extension by CR
[216]. Another study reports absence of a role for Sir2 in chronological
aging (long term survival of non-dividing cells) in yeast unlike its role
in replicative aging [218]. Increased Sir2 gene content also extended
life span in C. elegans [16] and Drosophila [206]. In C. elegans, SiR2.1
activated DAF-16 [219], a forkhead transcription factor, that mediates
life span regulation by insulin/IGF-1 signaling pathway [220]. Activating
autophagy is one of the underlyingmechanisms suggested to be behind
life span extension beneﬁts of Sir2 [221]. In Drosophila, overexpression
of Sir2 in adult fat body but not inmuscle promoted longevity indicating
tissue speciﬁc effects of Sir2 expression [222,223]. In humans, SIRT1
expression and activity are abrogated in aged arteries suggesting its
role in vascular aging [224]. SRT1720, a small molecule activator of
SIRT1, improved health and life span of mice, further suggesting the
role of SIRT1 [225]. Interestingly a positive correlation exists between
mitotic activity and SIRT1 levels in mammalian tissues [226]. The
anti-aging effect of SIRT1 likely involves p53, as SIRT1 was found to
antagonize promyelocytic leukemia protein (PML) induced acetylation
of p53 and cellular senescence in primary mouse embryo ﬁbroblasts
[227]. Another plausiblemechanism is through repressing PPARγ there-
by attenuating adipogenesis and promoting fat mobilization in white
adipocytes [168].
SIRT2 is reportedly elevated in the white adipose tissue and kidney
of caloric restricted mice where it deacetylates FOXO transcription
factors and increases expression of FOXO target genes, p27(Kip1),
manganese superoxide dismutase and Bim [100]. Cohen and colleagues
recently showed that SIRT6 overexpression in male mice extended life
span compared to wild type mice and this was associated with lower
serum levels of insulin-like growth factor 1 (IGF1) [18]. They also had
observed an increased SIRT6 levels following caloric restriction in rats
[228]. Accumulating evidences also suggest a role for SIRT3 in age
related pathologies [229,230]. Interestingly both mammalian SIRT3
and bacterial CobB regulate acetyl-CoA synthetase through its
deacetylation suggesting an evolutionary conservation of the mecha-
nism. Although sirtuins possess anti-aging functions from yeast to
mammals, the underlying mechanisms have also evolved to meet the
complexity of higher order species. In yeast, sirtuinsmainly act through
suppressing genomic instability (recombination mainly at the ribosom-
al DNA locus) where as in mammals they affect multiple pathways to
regulate aging.
Aging has been described to be characterized by declining NAD+,
delinking PGC-1α/β from mitochondrial control and the emergence of
a pseudo-hypoxic state [210,231]. Further, the pseudo-hypoxic state
was compared to Warburg reprogramming and was suggested to be
reﬂected in SIRT1 deﬁciency which may be restored with NAD+
augmentation. This has parallels to injury conditions manifested by
hypoxia and nutrient deprivation in downstream tissues and therefore
SIRT1 mediated metabolic regulation in tissue injury and repair draws
attention for investigations.
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Sirtuins are key physiological modulators controlling a number of
critical metabolic pathways and functions including cell death and
repair. These physiological regulations occur by virtue of their direct
enzymatic action on target proteins as well as due to alterations in the
level of metabolites related to the reaction. Though not all sirtuins are
robust deacetylases, the network of proteins that include PGC-1α,
SIRT1 and AMPK are considered to be a critical part of the energy sens-
ing network in cells [232]. SIRT1 and AMPK act as metabolic sensors by
their ability to deacetylate and phosphorylate, respectively, the mito-
chondrial biogenesis factor PGC-1α. Therefore the actions of SIRT1 are
closely linked to enhancement ofmitochondrial function and biogenesis
andmitigation of redox injurymaking this protein an attractive target in
molecular therapeutics [233]. It is further substantiated by the observa-
tion that following cellular stress SIRT1 activity is altered and modula-
tion of the activity and or expression of SIRT1 following cellular injury
is important in restoring cellular homeostasis, repair and death.
2.4. Sirtuins and cardiac injury
Several studies, including those fromour lab, have demonstrated the
importance of sirtuins in improving organ function and survival follow-
ing tissue injury [234–236]. In post myocardial infarction (MI) patients,
ischemia/reperfusion (I/R) injury remains the major cause for cardiac
remodeling and heart failure [237]. Therefore methods to prevent I/R
injury become instrumental in reducing mortality in post MI patients.
Numerous studies have been reported on the role of sirtuins, speciﬁcally
SIRT1, in managing I/R injury [234,238,239].
I/R injury was associated with a reduction in SIRT1 mRNA and pro-
tein [234]. Using transgenic mice with cardiac speciﬁc over expression
of SIRT1, Hsu et al. clearly demonstrated a signiﬁcant reduction in
myocardial infarction area and a greater recovery after reperfusion of
isolated hearts, compared to wild type. Conversely, cardiac speciﬁc
knockdown of SIRT1 resulted in increased size of myocardial infarc-
tion/area. The observed effects of SIRT1 overexpression is attributed to
suppression of oxidative stress and apoptosis by FOXO1 mediated
upregulation of antioxidant molecules like manganese superoxide
dismutase and down regulation of proapoptotic molecules [234]. One
of the prominent changes that occurs during cardiac hypertrophy is
the shift in myosin isoform from α- to β-myosin heavy chain (MHC)
[240]. Interestingly, fructose feeding was shown to have a protective
effect on the heart following I/R injury by inducing cardiac α-MHC
expression. Fructose feeding also stimulated cardiac NAD+ and SIRT1
levels and these effects were mimicked by resveratrol [241]. The role
of SIRT1 inα-MHC expressionwas further conﬁrmed by cardiac speciﬁc
overexpression studies. It is interesting to note that both a direct agonist
of SIRT1 (resveratrol) and its indirect activation by NAD+ levels could
cause similar physiological effects in tested animals. However the
mechanism of SIRT1 mediated induction of α-MHC expression is still
unclear.
Ischemic preconditioning (IPC) is effective in limiting cardiac
damage occurring during prolonged occlusion and reperfusion [237].
Nadtochiy et al. studied the role of SIRT1 in cardioprotective effects of
acute IPC using SIRT1 deﬁcient and SIRT1 overexpressing mice.
Consistent with a role for SIRT1, IPC induced cytosolic lysine
deacetylation in wild type hearts whereas SIRT1 deﬁcient hearts had
more cytosolic lysine acetylation and were refractive to precondition-
ing. Conforming to these results, SIRT1 overexpressing mice exhibited
decreased cytosolic acetylation and endogenous protection against I/R
injury [238]. Both IPC induced lysine deacetylation and cardiac protec-
tion was inhibited by SIRT1 inhibitor splitomycin [238]. Nicotinamide
phosphoribosyltransferase (Nampt), a key enzyme in the salvage
pathway of NAD synthesis, is a critical regulator of energy status and
survival in cardiac myocytes [242]. Nampt was found to play a crucial
role in mediating the protective effect of IPC against ischemia andreperfusion, which was also mimicked by exogenous nicotinamide
mononucleotide (NMN), a product of Nampt in the NAD+ salvage
pathway. On the other hand, Nampt can be secreted from
cardiomyocytes to act as a proinﬂammatory cytokine. The exogenous
Nampt was found to be a positive regulator of cardiac hypertrophy
and adverse ventricular remodeling [243]. Therefore, although intracel-
lular Nampt is essential to the cardiac myocyte survival, exogenous
Nampt could be detrimental demanding ﬁne balance between its
synthesis and secretion. Interestingly, the cardiac protection conferred
by IPC deteriorates with age [244]. The lack of ischemic tolerance in
aged hearts is mainly accounted for by a reduced SIRT1 expression
and activity although one study has ruled out the role of SIRT1 [244].
Caloric restriction (CR) was previously shown to increase longevity
in yeast and other species [207,245,246]. Shinumura et al. studied the
effects of short-term [247] and long-term caloric restriction [248] on is-
chemic tolerance and ischemic preconditioning (IPC) in aged rats.
Short-term CR improved left ventricular function in both young and
aged rats whichwas associated with an increase in AMPK phosphoryla-
tion [247]. Long term caloric restriction also improved recovery of left
ventricular function and reduced infarct size after ischemia–reperfu-
sion. However these changes were not associated with any changes in
expression of myocardial total or phosphorylated AMPK. Strikingly,
long-term CR induced cardiac protection was associated with nitric
oxide-dependent increase in nuclear SIRT1 content [248]. CR mediated
protection against I/R injury was associated with Nampt upregulation
whereas the protective effect was abrogated in SIRT1−/− mice,
suggesting a Nampt-SIRT1 axis [249]. Analysis of themolecular changes
underlying CR induced cardioprotection revealed an overall reduction
in acetylated mitochondrial proteins with CR. Consistent with a role
for sirtuins, deacetylation of speciﬁc proteins of the electron transport
chain was observed, which preserves mitochondrial integrity by
preventing accumulation of toxic ROS [250]. Deacetylation ofmitochon-
drial proteins also implies an involvement of mitochondrial sirtuins
apart from nuclear/cytoplasmic sirtuins like SIRT1.
Studies from our laboratory using a hemorrhagic shock model
showed that when 60% of the blood volume was removed from rats
and subjected to a prolonged shock phase, there was a signiﬁcant
decline in SIRT1 and PGC-1α protein levels in the heart at two hours
following resuscitation [235]. It is unclear whether this is the effect of
oxidative stress associated with resuscitation or initiated by the hypox-
ic/ischemic condition due to hemorrhagic shock. However, administra-
tion of resveratrol, a SIRT1 activator and antioxidant, along with
resuscitation ﬂuid proved to be beneﬁcial in improving left ventricular
function and cardiac contractility, and prolonged lifespan in the absence
of resuscitation [235,251]. Furthermore, hemorrhagic shock induced a
shift in the metabolic process towards glycolysis, consistent with a
mitochondrial functional decline which was restored by resveratrol
administration [252]. Other investigators have also observed the bene-
ﬁcial effect of resveratrol following hemorrhagic shock, thoughmethod-
ologies varied [253–255]. Resveratrol pretreatmentwas also effective in
reducing IR-induced arrhythmias andmortality in rats [80]. Resveratrol
was protective against myocardial injury in a rat model of autoimmune
myocarditis [81]. The SIRT1 activator resveratrol has been extensively
used in aging and injury conditions and at least part of the health effect
of resveratrol is likely through activation of SIRT1.
SIRT1 exerts its beneﬁcial effects at both transcriptional level and
posttranslational levels. At the transcriptional level, it affects the expres-
sion of many antioxidant genes and apoptotic molecules by stimulating
the transcriptional activity of FOXO1 [234]. Rui-HongWang et al. found
that hepatic SIRT1 deﬁciency in mice can impair mTorc2/Akt signaling
leading to oxidative damage and insulin resistance [256]. At the post-
translational level, SIRT1 inﬂuences acetylation and activity of a number
of proteins. Likewise the regulation of SIRT1 exists at multiple levels.
Aldehyde mediated carbonyl stress is considered as yet another factor
contributing to increased susceptibility of aging heart to I/R injury
[174]. Carbonyl modiﬁcation of SIRT1 during aging impairs its activity
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cardiac aldehyde dehydrogenase activation [174]. Therefore more stud-
ies are required to address the posttranslational changes in SIRT1 and
other sirtuins that may affect their compartmentalization and function
inside the cells. In cardiac myocytes SIRT1 expression is regulated by
microRNA, miR199a. miR199a itself is markedly down regulated during
cardiac ischemia which favors rapid accumulation of HIF-1α by
preventing its degradation [257].
Several endogenous and exogenous molecules have been shown to
exercise cardio protective effects through SIRT1 regulation. For example
locally acting insulin-like growth factor-1 isoform has been shown to
protect cardiomyocytes from oxidative/hypertrophic stress through
SIRT1 activation [258]. SIRT1 induction by resveratrol is reported to
have a modulatory effect on mitogen-activated protein kinase (MAPK)
pathway which is commonly upregulated under stress [259]. Likewise
sildenaﬁl, a phosphodiesterase-5 inhibitor improves I/R injury and a
concomitant SIRT1 activation was observed [260]. Cardiomyocyte
apoptosis is a characteristic feature of heart failure. Silibinin, a plant
ﬂavonoid was found to ameliorate β-adrenergic agonist isoproterenol-
induced injury in cultured rat neonatal cardiac myocytes through
mechanisms including but not limited to upregulation of SIRT1 [261].
However, in one study it has been shown that constitutive SIRT1
overexpression resulted in impaired cardiac mitochondria and cardiac
dysfunction in response to pressure overload [262].
Other sirtuins are also gainingprominencewith respect to their roles
in managing the detrimental effects of hypoxic/ischemic and reperfu-
sion injury. One of the mitochondrial sirtuins, SIRT4 was shown to
play a protective role in hypoxia induced apoptosis in H9c2
cardiomyoblast cells [263]. Similarly, another mitochondrial sirtuin,
SIRT5 undergoes marked downregulation in cardiomyocyes upon
oxidative stress [264]. Both SIRT4 and SIRT5 knockdown signiﬁcantly
increased apoptosis in cardiomyocytes [263,264]. The mitochondrial
sirtuin, SIRT3 is increasingly recognized as an important molecule in
preserving mitochondrial integrity and improving cardiac function.
Case studies on post MI patients indicate that exercise training exerts
beneﬁcial effects on improving cardiac functions [265,266]. Jiang et al.
studied the molecular basis of cardioprotection by aerobic interval
training (AIT) exercise in rat models. They found increased mitochon-
drial biogenesis in AIT rats accompanied by AMPK phosphorylation
and increased SIRT3 levels [267]. A recent report shows the protective
effect of resveratrol in combating oxidative stress by upregulating
SIRT3 expression in the mitochondria of human vascular endothelial
cells [268]. Flavanoids like rhamnetin also exhibit cyto protective effects
against oxidative stress in H9c2 cardiomyoblasts by SIRT3 and SIRT4
induction [269]. Consistent with these observations, SIRT3 deﬁcient
hearts were less tolerant to I/R injury with greater infarct size [270].
This decline in function is attributed to inhibition of enzymatic activities
of SIRT3 targets Cx1 and Mn SOD. SIRT3 knockdown in H9C3 cardiac
cells made them more vulnerable to oxidative damage [270]. Together
these results suggest that SIRT3 may be an important component of
damage control in I/R and other forms of injury and demand more
attention. SIRT7 is yet another sirtuin with a profound effect on
preventing apoptosis and inﬂammatory cardiomyopathy; the observed
effects likely mediated through its effect on p53 deacetylation [148].
2.5. Sirtuins and neuronal injury
The neuroprotective effects of SIRT1 have been demonstrated in dif-
ferentmodels of traumatic brain injury, ischemic injury and in a number
of neurodegenerative disorders. Ischemic brain damage often leads to
fatal outcomes unless managed in a narrow window of time [271,
272]. Therefore, studies to identify novel strategies to manage ischemic
damage would have important clinical implications [273,274]. Like in
hearts, ischemic preconditioning is found to be an effective strategy in
protecting neurons from lethal ischemia. An in vitro model of cerebral
ischemia using hippocampal slice cultures subjected to oxygen-glucose deprivation (OGD) is a useful alternative to in vivo ischemia
[275]. Initial studies by Raval and colleagues using this in vitro model
conﬁrmed neuroprotective action of SIRT1 agonist resveratrol in
cerebral ischemia [272,276]. Both IPC and resveratrol preconditioning in-
duced neuroprotection were accompanied by SIRT1 activation and con-
comitant reduction in uncoupling protein 2 levels [239]. Ischemic brain
injury leads to brain cell apoptosis by poly(ADP-ribose)polymerase
(PARP) activation which depletes intracellular NAD+ [277]. NAD+
replenishment could reduce ischemic injury by OGD in in vitro cultures
of primary neurons [278] and also in rat model of focal ischemia [279].
The positive effects of NAD+ repletion is mimicked by overexpression
of Nampt. Nampt overexpression induced neuroprotection was
dependent on SIRT1 mediated LKB1 deacetylation and AMPK activation
[74]. A later study also showed the involvement of autophagy in the
neuroprotection conferred by Nampt in cerebral ischemia. Overexpres-
sion of Nampt enhanced autophagy in a SIRT1 dependent manner
through TSC2–mTOR–S6K1 signaling pathway [280]. Analyzing the
signaling pathways modulated by resveratrol in the ischemic brain con-
cluded an increase in Akt and p38MAPK phosphorylation and a decrease
in ERK1/2 phosphorylation. Additionally the expression of SIRT1, PGC-1α
and phosphorylation of cyclic AMP-response-element-binding protein
were augmented with a reduction in anti-apoptotic Bcl2 transcription
[281]. A direct role for SIRT1 in stroke is evident from studies that show
greater infarct size in SIRT1 knockout mice that underwent middle cere-
bral artery occlusion compared to wild type mice [282,283]. The infarct
volume was also affected by pharmacologic modulation of SIRT1; SIRT1
activator A3 decreased infarct volume whereas sirtinol increased the
infarct volume. An increase in acetyation of p53 and NFκB explains the
exacerbated injury upon SIRT1 deletion [283]. Recent reports highlight
the role of SIRT1 in preserving cerebral blood ﬂow following cerebral
hypoperfusion injury [284,285]. These vasculoprotective effects of SIRT1
are likely mediated through its deacetylation of brain endothelial nitric
oxide synthase. Traumatic brain injury (TBI) is another domain where
SIRT1 action comes to the limelight. SIRT1 induction seen in TBI is crucial
in preventing neuronal apoptosis and this protection is lostwith SIRT1 in-
hibition [286]. Taken together these studies indicate an indispensable
role for SIRT1 activation in reversing brain damage.
Several natural products and neuroprotective agents have been
shown to act through SIRT1. For instance, SIRT1 up regulation is in-
volved in the neuroprotective effects of 2,3,5,4′-tetrahydroxystilbene-
2-O-beta-D-glucoside (TSG) [287] and icarin [288] against ischemic
brain injury. Epigallocatechin-3-gallate, a component of tea polyphe-
nols conferred protection in an in vitro model of neuronal cell injury
by stimulating SIRT1 and PGC-1α levels and suppressing ROS produc-
tion [289]. SIRT1 is also augmented with vitamin E supplementation
that alleviates oxidative damage following mild traumatic brain injury
[290]. Adipokine leptin showed neuroprotection in permanent middle
cerebral artery occlusion accompanied by increased SIRT1 expres-
sion [291]. Erythropoietin is yet another hormone which protects
against brain injury by SIRT1 activation [292]. In fact SIRT1 behaves
like a sensor that helps the cells adapt to environmental changes.
Several dietarymodiﬁcationswhich cause cellular oxidative imbalances
have been linked with changes in SIRT1 levels. For example a high fat
diet diminished SIRT1 expression in hippocampus and cerebral cortex
whichwas reversed by vitamin E supplementation [293]. SIRT1 expres-
sion in hippocampus was reduced in mild traumatic brain injury and
was restored by omega-3 fatty acids supplementation [294]. Similar to
hearts, caloric restriction offers protection against ischemia-induced
neurodegeneration. Rats subjected to short term food restriction
displayed improved recovery in terms of spatial learning and memory
following ischemia [295]. However the role of sirtuins in these protec-
tive effects is yet to be determined.
The SIRT1 protective effects are implicated in neurodegenerative
diseases like Alzheimer's [296,297], Parkinson's [298], Huntington's
disease [299], Amyotrophic lateral sclerosis [300], Multiple sclerosis
[301] and prion diseases [302]. Alzheimer's and Parkinson's are often
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self-destruction. Rapid Wallerian degeneration is observed in axons
and their synapses distal to an injury whereas Wallerian degeneration
slow (wlds) mice are protected from axonal degeneration [303].
Nicotinamide mononucleotide adenylyltransferase1 (Nmnat1) is a key
enzyme involved in the NAD biosynthetic pathway in the nucleus. An
increased Nmnat1 activity and SIRT1 activation is accounted for the ax-
onal protection in wlds mice [274]. These studies clearly underscore a
prominent role for SIRT1 in conferring neuroprotection. However,
SIRT1 also sensitizes neurons to oxidative damage by deacetylating
IRS-2 and reducing activation of the Ras/ERK1/2 pathway, hinting at a
pro-aging role [304].
Apart from cardio and neuroprotective effects, sirtuins have been
shown to play important roles in injuries to other organs. Renal speciﬁc
overexpression of SIRT1 conferred considerable protection from cisplat-
in induced acute kidney injury (AKI). These protective effects of SIRT1
were mediated through a reversal of peroxisome number and function,
mitochondrial function, attenuation of ROS and apoptosis [305].
Conforming to the above study, SIRT1−/−mice were more susceptible
to unilateral ureteral obstruction (UUO) model of kidney injury. The in-
creased susceptibility to injury in SIRT1 deﬁcient mice is attributed to
diminished Cox2 expression and increased apoptosis and ﬁbrosis. Op-
posite effects were observed with SIRT1 pharmacologic activation
with resveratrol or SRT2183 [306]. Resveratrol also protected mouse
proximal tubular cells from cisplatin induced renal injury through p53
deacetylation and apoptosis, further conﬁrming the role of SIRT1 in
p53mediated apoptosis [307]. Not only does cisplatin increases acetyla-
tion of p53 but also induces acetylation of p65 subunit of NF-κB both of
which accounts for the cytotoxic effects of cisplatin. Overexpression of
SIRT1 in renal proximal tubule cells signiﬁcantly attenuated the cyto-
toxic effects of cisplatin by NF-κB deacetylation [308]. Although, beneﬁ-
cial effects of resveratrol are well evident in diabetic nephropathy, it is
also suggested to be independent of SIRT1 [309]. Resveratrol feeding
in db/db mice signiﬁcantly improved mitochondrial oxidative stress
and associated pathologies but failed to enhance AMPK activation or
SIRT1 expression in the kidney precluding a role for SIRT1 [309]. Since
this study has not tested SIRT1 activity in the kidney, the role of SIRT1
inmediating resveratrol effects cannot be ruled out. In stark contrast an-
other study clearly shows the involvement of AMPK–SIRT1–PGC1α axis
in the salutary effects of resveratrol in diabetic nephropathy [310].
Sirtuin family of proteins are important physiological modulators
and play critical roles in cellular homeostasis. Though SIRT1 is among
the most studied sirtuins, the role of other sirtuins and small molecule
modulators of sirtuins in cell survival, growth, proliferation and death
is being investigated by many laboratories and the information gained
will allow us to better understand the molecular processes in aging
and injury. The profound effect of some of the sirtuins, such as SIRT1
and SIRT3, in regulating mitochondrial function and cellular energetics
makes these proteins important players in determining outcome fol-
lowing cell, tissue and organ injury. Declining mitochondrial function
is a hallmark of both aging and injury and therefore, further studies on
the regulation of sirtuin family of proteins remain important.Transparency document
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